CRS is the most common systemic inflammatory response after CAR-T therapy, characterized by the release of large amounts of inflammatory cytokines such as IL-2, IL-6, IL-10, INF-γ, TNF-α, and C-reactive protein (CRP), along with the local recruitment of immune cells, which can induce a localized cytotoxic response. Here, CRP is linked to congenital rubella syndrome.